3 Best Stocks Now to Soar from Covid

Many stocks will benefit from the rollout of the Covid 19 vaccine.

According to a Bank of America research note, “Companies in bioprocess and manufacturing may see revenues if a vaccine is produced at risk and never approved, while others, like drugstores, benefit only if people are vaccinated,” the team wrote. “Logistics companies tend to be somewhere in the middle, benefiting from some at-risk production but ultimately, the vaccine needs to be consumed and re-ordered for real benefits to accrue.”

Of the names they mention, I’ve filtered down to the ones which meet my tighter filters of cash flow growth, earnings growth, and a share price which is not high relative to profits the company makes.

Market cap: $158.97 billion

Vaccine revenue opportunity: $1.3 billion – $2.4 billion (base case); $5.3 billion – $9.9 billion (bull case)

Vaccine supply chain category: Manufacturing

Source: Bank of America

https://t.me/pipspredator

Market cap: $186.86 billion

Vaccine revenue opportunity: $1.3 billion – $2.4 billion (base case); $5.3 billion – $9.9 billion (bull case)

Vaccine supply chain category: Manufacturing

Source: Bank of America

Market cap: $209.93 billion

Vaccine revenue opportunity: $1.3 billion – $2.4 billion (base case); $5.3 billion – $9.9 billion (bull case)

Vaccine supply chain category: Manufacturing

Source: Bank of America

Source: Bank of America, Business Insider

Alpesh Patel

www.alpeshpatel.com